Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nesp Biosame to Hit Japan Shelves on August 5
Nearly a year after its first-of-a-kind approval and ensuing debates surrounding its pricing, the so-called “biosame” version of Kyowa Kirin’s flagship renal anemia drug Nesp (darbepoetin alfa) will finally arrive on the Japanese market on August 5. “We developed this…
To read the full story
Related Article
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- Kyowa Kirin Nets 12.6% Growth on Positive Sales Overseas; Biosame Trounces Nesp in Q4
February 6, 2020
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Kissei to Leverage Its Track Record with EPO to Promote Nesp Biosimilar: President
October 4, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Chuikyo OKs 70% Pricing for Nesp Biosame; New Rules Up for FY2020 Reform Debate
March 28, 2019
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
BUSINESS
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…